CLAIMS

1. A pharmaceutical composition for intrauterine cavity administration which comprises adipose tissue derived reproductive cells including adipose stem cells, vascular endothelial cells and vascular pericytes, and is used for treatment of infertility.

2. The pharmaceutical composition according to claim 1, further comprising at least one selected from the group consisting of glycosaminoglycan and a derivative of the glycosaminoglycan.

3. The pharmaceutical composition according to claim 2, wherein the glycosaminoglycan is hyaluronic acid.

4. The pharmaceutical composition according to any one of claims 1 to 3, further comprising an estrogen receptor activating factor.

5. The pharmaceutical composition according to claim 4, wherein the estrogen receptor activating factor is estrogen.

6. The pharmaceutical composition according to any one of claims 1 to 5, which is used for amelioration of an implantation failure.

7. The pharmaceutical composition according to any one of claims 1 to 6, which has an angiogenesis inducing action.

8. The pharmaceutical composition according to any one of claims 1 to 7, which has an endometrial proliferation capability.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the adipose tissue derived reproductive cells are prepared at time of use, or are frozen.

10. A method for producing the pharmaceutical composition according to any one of claims 1 to 9, the method comprising:

treating an adipose tissue with a disaggregation agent to obtain a disaggregated tissue;

concentrating reproductive cells from the disaggregated tissue by centrifugal separation treatment; and

recovering concentrated reproductive cells.

11. The method according to claim 10, wherein the adipose tissue is derived from a subcutaneous tissue.